Watanabe M, Sugimoto Y, Tsuruo T
Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, Tokyo.
Cancer Res. 1990 Oct 15;50(20):6657-62.
In the previous study, we generated a monoclonal antibody, 8F11, against NL-17, a high metastatic clone derived from a metastatic variant of murine colon adenocarcinoma 26. 8F11 inhibited platelet aggregation induced by NL-17 and recognized a Mr 44,000 membrane protein as antigen. In the present study, the reactivity of 8F11 to murine B16 melanoma and its metastatic variants was examined, and the antigen recognized by 8F11 on the cell surface was characterized. 8F11 was found to strongly react with 3 metastatic variants of B16 melanoma. In contrast, only slight reactivity was observed with parent B16 melanoma. The reactivity of the antibody to these cells was in the order B16F10 greater than B16BL-6 greater than B16F1 much greater than B16. Western blot analysis showed a Mr 41,000 protein as the antigen recognized by 8F11 on the cell surface of B16F10 cells. The Mr 41,000 antigen appeared to be a glycoprotein that bound to wheat germ agglutinin as has been observed for the Mr 44,000 antigen of NL-17. To elucidate the functional role of the Mr 41,000 antigen in B16 melanoma, platelet aggregation induced by B16 and B16F10 was compared. B16 was reported to stimulate platelet aggregation by the generation of thrombin, whereas B16F10 was found to activate platelet by at least 2 mechanisms: one dependent on thrombin and the other independent on thrombin. The activity of B16 and its metastatic variants to induce platelet aggregation in the presence of MD805, a synthetic antagonist of thrombin, well correlated with the reactivity of 8F11 to these cells. 8F11 blocked platelet activation by B16F10 under conditions preventing thrombin activity such as enzymatic formation of lysolecithin through the treatment of the cell surface with phospholipase A2 or in the presence of MD805. These data indicate that Mr 41,000 glycoprotein recognized by 8F11 on metastatic variants of B16 melanoma is involved in the thrombin-independent platelet aggregation. A positive correlation was observed between the levels of Mr 41,000 glycoprotein expression of B16 and its metastatic variants and their pulmonary metastasis after i.v. injection, suggesting Mr 41,000 glycoprotein, as well as other factors reported previously, may play an important role in the hematogenous spread of B16 melanoma.
在先前的研究中,我们制备了一种针对NL-17的单克隆抗体8F11,NL-17是源自小鼠结肠腺癌26转移变体的高转移克隆。8F11抑制NL-17诱导的血小板聚集,并识别一种分子量为44,000的膜蛋白作为抗原。在本研究中,检测了8F11与小鼠B16黑色素瘤及其转移变体的反应性,并对8F11在细胞表面识别的抗原进行了表征。发现8F11与B16黑色素瘤的3种转移变体强烈反应。相比之下,与亲本B16黑色素瘤仅观察到轻微反应。该抗体对这些细胞的反应性顺序为B16F10大于B16BL-6大于B16F1远大于B16。蛋白质印迹分析显示,在B16F10细胞表面,一种分子量为41,000的蛋白质是8F11识别的抗原。分子量为41,000的抗原似乎是一种糖蛋白,它与麦胚凝集素结合,正如在NL-17分子量为44,000的抗原中所观察到的那样。为了阐明分子量为41,000的抗原在B16黑色素瘤中的功能作用,比较了B16和B16F10诱导的血小板聚集。据报道,B16通过凝血酶的产生刺激血小板聚集,而发现B16F10通过至少2种机制激活血小板:一种依赖于凝血酶,另一种不依赖于凝血酶。在存在凝血酶合成拮抗剂MD805的情况下,B16及其转移变体诱导血小板聚集的活性与8F11对这些细胞的反应性密切相关。在防止凝血酶活性的条件下,如通过用磷脂酶A2处理细胞表面或在存在MD805的情况下,8F11阻断了B16F10诱导的血小板活化。这些数据表明,8F11在B16黑色素瘤转移变体上识别的分子量为41,000的糖蛋白参与了不依赖凝血酶的血小板聚集。在静脉注射后,观察到B16及其转移变体的分子量为41,000的糖蛋白表达水平与其肺转移之间呈正相关,这表明分子量为41,000的糖蛋白以及先前报道的其他因素可能在B16黑色素瘤的血行转移中起重要作用。